Honored to Partner with LLS Therapy Acceleration Program for Transformative Cancer Therapies – Auron Therapeutics, Inc.
Auron Therapeutics, Inc. shared a post on LinkedIn:
“We’re honored to be supported by The Leukemia & Lymphoma Society through their prestigious Therapy Acceleration Program (TAP)!
LLS TAP’s investment in Auron supports the rapid development of our Phase 1 AUTX-703 for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
This partnership brings more than funding – we gain access to LLS’s unparalleled expertise in blood cancer research and their deep understanding of patient needs. Together, we’re working to bring transformative therapies to patients who need them most.”
Blaine Robinson, Vice President of Therapy Acceleration Program at The Leukemia & Lymphoma Society, shared a post by Auron Therapeutics, Inc., adding:
“Looking forward to working closely with Auron Therapeutics, Inc., our newest biotech partner through our Therapy Acceleration Program (TAP) here at The Leukemia & Lymphoma Society.
A great example of the type of team and company we’re looking for to make investments to help bring innovative therapies to blood cancer patients.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023